EFFECT OF BETA-ENDORPHIN ON HUMAN CHORIONIC-GONADOTROPIN SECRETION BY PLACENTAL EXPLANTS

被引：11

作者：

BARNEA, ER

ASHKENAZY, R

TAL, Y

KOL, S

SARNE, Y

机构：

[1] University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School at Camden, Cooper Hospital/University Medical Center, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Fertility, Camden, NJ

[2] Feto-Placental Endocrine Unit, Rappaport Institute Technion, Rh Efron, Haifa

[3] Department of Physiology, Sackler School of Medicine, Tel Aviv University, Tel Aviv

来源：

HUMAN REPRODUCTION | 1991年 / 6卷 / 09期

关键词：

BETA ENDORPHIN; HCG; INVITRO; PLACENTA;

D O I：

10.1093/oxfordjournals.humrep.a137534

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

In the present study the effect of physiological concentrations of beta-endorphin was examined upon human chorionic gonadotrophin (HCG) secretion by first trimester placental explants. Results show that at 7-9 weeks of gestation, beta-endorphin inhibited HCG secretion; a maximal suppression of 60% was noted at 5 X 10(-10) M concentrations, while fivefold lower or higher doses were less effective. This inhibitory effect was completely reversed by naloxone, an opiate receptor antagonist, indicating involvement of an opiate receptor in the action of beta-endorphin. The opioid peptide specificity was demonstrated by the failure of N-acetyl-beta-endorphin, a non-opiate analogue used at the same concentration range, to affect HCG secretion. Following the HCG peak, at 11 weeks however, the effect of beta-endorphin was stimulatory on HCG secretion, which suggests a gestational age-dependent effect of the opioid peptide. In conclusion, these data indicate that beta-endorphin, a mu and delta-opioid receptor ligand, has a modulatory effect on HCG secretion in vitro in the young placenta.

引用

页码：1327 / 1331

页数：5

共 20 条

[11]

Lemaire S., Valette A., Chouinard L., Dupuis N., Day R., Porthe G., Cros J., Purification and identification of multiple forms of dynorphin in human placenta, Neuropeptides, 3, pp. 181-191, (1983)

[12]

Lowry O.H., Rosebrough N.A., Farr A.L., Randall R.J., Protein measurements with the pholin phenol reagent, J. Biol. Chem., 193, pp. 265-274, (1951)

[13]

Maruo T., Matsuo H., Ohtani T., Hoshina M.H., Mochizuki M., Differential modulation of chorionic gonadotropin (CG) subunit messenger ribonucleic acid level and CG secretion by progesterone in normal placenta and choriocarcinoma cultured in vitro, Endocrinology, 119, pp. 858-864, (1986)

[14]

Nakai Y., Nakao K., Oki S., Imura H., Presence of immunoreactive β-lipotropin and β -endorphin in human placenta, Life Sci., 23, pp. 2013-2018, (1978)

[15]

Odagiri E., Sherrel B.J., Mount C.D., Nicholson W.E., Orthe D.N., Human placental immunoreactive corticotropin, lipotropin, and β-endorphin: Evidence for a common precursor, Proc. Natl. Acad. Sci. USA, 76, pp. 2027-2031, (1979)

[16]

Petraglia F., Vaughan J., Vale W., Steroid hormones modulate the release of immunoreactive gonadotropin-releasing hormone from cultured human placental cells, J. Clin. Endocrinol. Metab., 70, pp. 1173-1178, (1990)

[17]

Porthe G., Valette A., Cros J., Kappa opiate binding sites in human placenta. Biochem. Biophys. Res, Common., 101, pp. 1-6, (1981)

[18]

Sastry B.V.R., Barnwell S.L., Tayeb O.S., Janson V.E., Owens L.K., Occurrence of methionine enkephaline in human placental villus. Biochem, Pharmacol., 29, pp. 475-478, (1980)

[19]

Valette A., Pontonnier G., Cros J., Evidence for a stereospecific [3H]etorphine binding in human placenta, FEBS Lett., 103, pp. 362-365, (1979)

[20]

Valette A., Tafani M., Porthe G., Pontonnier G., Cros J., Placenta] kappa binding site: Interaction with dynorphin and its possible implication in hCG secretion, Life Sci., 33, pp. 523-526, (1983)

← 1 2 →